Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

Halozyme Therapeutics in the NEWS
Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain has approved Roche's (This content is for paid subscribers.

Please click here to subscribe or here to log in.